•
Jun 30, 2023
Atea Q2 2023 Earnings Report
Atea Pharmaceuticals reported financial results for the second quarter ended June 30, 2023.
Key Takeaways
Atea Pharmaceuticals reported their Q2 2023 financial results, highlighting the continued advancement of the Phase 3 SUNRISE-3 trial for COVID-19 and the progress of their Phase 2 combination study for Hepatitis C.
Enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19.
Phase 3 SUNRISE-3 trial protocol amended to broaden eligibility criteria for high-risk patients and adapt to current COVID-19 environment.
Enrollment continues in Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of hepatitis C (HCV) with initial results expected in 4Q23.
Cash, cash equivalents and marketable securities totaled $608.1 million at June 30, 2023.